Cureformin MC 500mg/750mcg Tablet SR
By Cureformin MC
Rx
10 Tablet SR in a Strip

Composition
Metformin(500mg) + Methylcobalamin(750mcg)

Manufacturer - Curega Healthcare Pvt Ltd
Office No -4, C/2 Building, Simplicity, Handewadi Road , Hadapsar, Pune - 412308 Maharashtra, India

Expires on or after
July, 2026

liver
For individuals with liver disease, it is important to use Cureformin MC 500mg/750mcg Tablet SR with caution. Patients with liver issues may require a dose adjustment when taking this medication. It is advised to consult your doctor before initiating treatment. Typically, Cureformin MC 500mg/750mcg Tablet SR is initially prescribed at a low dose for patients with mild to moderate liver conditions. However, it is not recommended for use in individuals with severe liver disease.

kidney
Cureformin MC 500mg/750mcg Tablet SR should be used carefully if you have kidney disease. Your doctor may need to adjust the dosage. Avoid using if you have severe kidney issues. Monitor your kidney function regularly during treatment.

alcohol
It is not safe to drink alcohol while taking Cureformin MC 500mg/750mcg Tablet SR.

driving
Caution for Driving Your driving ability may be influenced by low or high blood sugar levels. Avoid driving if experiencing these symptoms with Cureformin MC 500mg/750mcg Tablet SR.

pregnancy
It is important to note that Cureformin MC 500mg/750mcg Tablet SR may not be safe to use during pregnancy. Animal studies have indicated potential harm to the developing baby. Your doctor will evaluate the risks and benefits before recommending this medication. Kindly consult your doctor for further advice.

breastfeeding
Cureformin MC 500mg/750mcg Tablet SR is likely safe while breastfeeding. Limited data shows no significant risk to the baby.
Habit Forming | No |
Chemical Class | - |
Therapeutic Class | ANTI DIABETIC |
Action Class | - |
₹80
Inclusive of all taxes
Content verified by

Dr. Gowri Kulkarni
MBBS - General Medicine, DNB - Psychiatry, MRCGP [INT] Family Medicine, BSIC (BACP)
Last update on 01-Oct-2024